Search - tctmd.com

Displaying 1 - 20 of 28

Sort: Relevancy | Date

News Features

Top News in Coronary Artery Disease: 2018

Yael L. Maxwell

December 28, 2018

News Daily News

Many PCI Patients Treated in China Have No Angina Symptoms

Caitlin E. Cox

December 20, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2018

Shelley Wood

November 30, 2018

News Conference News AHA 2018

Rivaroxaban Lowers Thromboembolic Risk in HF Patients: COMMANDER HF

Todd Neale

November 11, 2018

News Daily News

Debate Over BMS vs DES in High-Bleeding-Risk Scenarios Gets Fresh Fuel in Meta-analysis

Yael L. Maxwell

November 05, 2018

News Conference News TCT 2018

Twitter, Bias, and Trial Tweaks: ISCHEMIA Invites Debate on Study Designs and Endpoint Combos

Michael O'Riordan

October 02, 2018

News Conference News TCT 2018

CorMicA Offers Glimmer of Hope for Testing, Treating Angina Without Obstructive CAD

Shelley Wood

September 26, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2018

Caitlin E. Cox

September 04, 2018

News Daily News

‘Immediate’ Return to Normal Flow Post-PCI in ORBITA-Like Patients

Michael O'Riordan

August 23, 2018

News Daily News

High-Sensitivity Troponin T Safely Rules Out More MI Patients, and Faster, Than Conventional Assay

Michael O'Riordan

August 14, 2018

News Daily News

Elevated High-Sensitivity CRP Lingers Long After MI, Observational Study Shows

Yael L. Maxwell

August 03, 2018

News Daily News

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Michael O'Riordan

July 06, 2018

News Daily News

New Review Probes Possibility of CVD Prevention Without Aspirin

Michael O'Riordan

July 04, 2018

News Daily News

Once Again, ISCHEMIA Trial Feels the Squeeze

Michael O'Riordan

June 29, 2018

News Daily News

Liability Reform Changes How Docs Manage Suspected Coronary Artery Disease

Michael O'Riordan

June 07, 2018

News Conference News EuroPCR 2018

ORBITA Deep Dive Highlights Treatment Choices, Social Media, and Ethics

Michael O'Riordan

May 31, 2018

News Conference News EuroPCR 2018

Modest Benefit of PCI Over Medical Therapy in Patients With ‘Grey Zone’ FFR Lesions

Michael O'Riordan

May 23, 2018

News Conference News EuroPCR 2018

FFR-Guided PCI Reduces Risk of Death/MI Compared With Medical Therapy: Pooled Analysis

Michael O'Riordan

May 22, 2018

News Daily News

ESC Consensus Statement Tackles Inflammation, Cholesterol Connection in a Post-CANTOS World

Caitlin E. Cox

May 16, 2018

News Daily News

FDA Advisory Panel Says Celecoxib Is as Safe for Heart as Ibuprofen and Naproxen

Michael O'Riordan

April 25, 2018

Advertisement

Top News in Coronary Artery Disease: 2018

Many PCI Patients Treated in China Have No Angina Symptoms

TCTMD’s Top 10 Most Popular Stories for November 2018

Rivaroxaban Lowers Thromboembolic Risk in HF Patients: COMMANDER HF

Debate Over BMS vs DES in High-Bleeding-Risk Scenarios Gets Fresh Fuel in Meta-analysis

Twitter, Bias, and Trial Tweaks: ISCHEMIA Invites Debate on Study Designs and Endpoint Combos

CorMicA Offers Glimmer of Hope for Testing, Treating Angina Without Obstructive CAD

TCTMD’s Top 10 Most Popular Stories for August 2018

‘Immediate’ Return to Normal Flow Post-PCI in ORBITA-Like Patients

High-Sensitivity Troponin T Safely Rules Out More MI Patients, and Faster, Than Conventional Assay

Elevated High-Sensitivity CRP Lingers Long After MI, Observational Study Shows

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

New Review Probes Possibility of CVD Prevention Without Aspirin

Once Again, ISCHEMIA Trial Feels the Squeeze

Liability Reform Changes How Docs Manage Suspected Coronary Artery Disease

ORBITA Deep Dive Highlights Treatment Choices, Social Media, and Ethics

Modest Benefit of PCI Over Medical Therapy in Patients With ‘Grey Zone’ FFR Lesions

FFR-Guided PCI Reduces Risk of Death/MI Compared With Medical Therapy: Pooled Analysis

ESC Consensus Statement Tackles Inflammation, Cholesterol Connection in a Post-CANTOS World

FDA Advisory Panel Says Celecoxib Is as Safe for Heart as Ibuprofen and Naproxen

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content